Sagility Limited has reported strong financial performance for the year ended March 31, 2026, with revenue reaching ₹71,929 million, representing a 29.1% growth over the previous year. The company also announced a final dividend of ₹0.10 per equity share and introduced the ‘ESOS 2026’ scheme to grant stock options and performance stock units to eligible directors and employees, underscoring its commitment to growth and talent retention.
Financial Highlights for FY26
Sagility Limited achieved significant growth in the fiscal year ending March 31, 2026. The company reported a total revenue of ₹71,929 million, a 29.1% increase compared to the previous fiscal year. Profitability also saw a strong uptick, with Adjusted PAT reaching ₹11,306 million, marking a 39.5% growth YoY. Furthermore, the company reported Adjusted EBITDA of ₹18,200 million, demonstrating strong operational efficiency.
Dividend and Shareholder Value
Reflecting its commitment to delivering value to shareholders, the Board of Directors has recommended a final dividend of ₹0.10 per equity share for the financial year ended March 31, 2026. This recommendation is subject to approval at the upcoming Annual General Meeting (AGM), with further details on the record date and payment timeline to be announced.
New Employee Incentive Scheme
The Board has approved the ‘Sagility Limited – Employee Stock Options and Performance Stock Units Scheme 2026’ (ESOS 2026). This initiative is designed to provide long-term incentives to eligible directors and employees, covering a pool of over 15.45 crore shares. The scheme aligns with the company’s goal to reward and retain key talent as it continues its expansion as a technology-led healthcare operations transformation partner.
Strategic Business Performance
Sagility’s growth continues to be driven by a strong focus on the U.S. healthcare market. The company added 17 new client groups during FY26, bringing the total to 82 active client groups. Additionally, the company is advancing its AI capabilities through its SmarTec and Synchrony solution suites, helping healthcare organizations effectively navigate rising medical costs and regulatory complexities.
Source: BSE
